BACKGROUND: Francisella tularensis, the causative agent of tularemia, is a highly virulent microbe. One significant virulence factor of F. tularensis is the O-polysaccharide (O-PS) portion of the organism's lipopolysaccharide. METHODS: A wzy (O-antigen polymerase) deletion mutant of Ft. live attenuated vaccine strain (Ft.LVS), designated Ft.LVS::Δwzy, was created and evaluated as a live attenuated vaccine. Specifically, the mutant's virulence potential and its protective efficacy against type A and type B strains were investigated by challenge of immunized mice. RESULTS: F. tularensis LVS::Δwzy expressed only 1 repeating unit of O-PS and yet, upon immunization, induced O-PS-specific antibodies. Compared with Ft.LVS, the mutant was highly sensitive to complement-mediated lysis, significantly attenuated in virulence, and was recovered in much lower numbers from the organs of infected mice. Intranasal immunization with Ft.LVS::Δwzy provided protection against subsequent intranasal infection with the highly virulent type A strain SchuS4 and with Ft.LVS. Immunization with Ft.LVS::Δwzy elicited both humoral and cell-mediated immunity. CONCLUSIONS: Ft.LVS::Δwzy was avirulent in mice and, despite expressing only 1 repeating unit of the O-PS, induced antibodies to the full-length O-PS. Vaccination with Ft.LVS::Δwzy protected mice against intranasal challenge with both type A and type B strains of F. tularensis and induced functional immunity through both humoral and cellular mechanisms.
BACKGROUND:Francisella tularensis, the causative agent of tularemia, is a highly virulent microbe. One significant virulence factor of F. tularensis is the O-polysaccharide (O-PS) portion of the organism's lipopolysaccharide. METHODS: A wzy (O-antigen polymerase) deletion mutant of Ft. live attenuated vaccine strain (Ft.LVS), designated Ft.LVS::Δwzy, was created and evaluated as a live attenuated vaccine. Specifically, the mutant's virulence potential and its protective efficacy against type A and type B strains were investigated by challenge of immunized mice. RESULTS:F. tularensis LVS::Δwzy expressed only 1 repeating unit of O-PS and yet, upon immunization, induced O-PS-specific antibodies. Compared with Ft.LVS, the mutant was highly sensitive to complement-mediated lysis, significantly attenuated in virulence, and was recovered in much lower numbers from the organs of infected mice. Intranasal immunization with Ft.LVS::Δwzy provided protection against subsequent intranasal infection with the highly virulent type A strain SchuS4 and with Ft.LVS. Immunization with Ft.LVS::Δwzy elicited both humoral and cell-mediated immunity. CONCLUSIONS: Ft.LVS::Δwzy was avirulent in mice and, despite expressing only 1 repeating unit of the O-PS, induced antibodies to the full-length O-PS. Vaccination with Ft.LVS::Δwzy protected mice against intranasal challenge with both type A and type B strains of F. tularensis and induced functional immunity through both humoral and cellular mechanisms.
Authors: D T Dennis; T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; A M Friedlander; J Hauer; M Layton; S R Lillibridge; J E McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; K Tonat Journal: JAMA Date: 2001-06-06 Impact factor: 56.272
Authors: Tae-Hyun Kim; Shite Sebastian; Jessica T Pinkham; Robin A Ross; LeeAnn T Blalock; Dennis L Kasper Journal: J Biol Chem Date: 2010-07-06 Impact factor: 5.157
Authors: Michael A Apicella; Deborah M B Post; Andrew C Fowler; Bradley D Jones; Jed A Rasmussen; Jason R Hunt; Sayaka Imagawa; Biswa Choudhury; Thomas J Inzana; Tamara M Maier; Dara W Frank; Thomas C Zahrt; Kathryn Chaloner; Michael P Jennings; Molly K McLendon; Bradford W Gibson Journal: PLoS One Date: 2010-07-06 Impact factor: 3.240
Authors: Yu Cong; Jieh-Juen Yu; M Neal Guentzel; Michael T Berton; Janakiram Seshu; Karl E Klose; Bernard P Arulanandam Journal: Vaccine Date: 2009-08-03 Impact factor: 3.641
Authors: Shite Sebastian; Jessica T Pinkham; Jillian G Lynch; Robin A Ross; Barbara Reinap; Leeann T Blalock; J Wayne Conlan; Dennis L Kasper Journal: Vaccine Date: 2008-11-18 Impact factor: 3.641
Authors: Leah E Cole; Yang Yang; Karen L Elkins; Ellen T Fernandez; Nilofer Qureshi; Mark J Shlomchik; Leonard A Herzenberg; Leonore A Herzenberg; Stefanie N Vogel Journal: Proc Natl Acad Sci U S A Date: 2009-02-26 Impact factor: 11.205
Authors: Mark E Marohn; Araceli E Santiago; Kari Ann Shirey; Michael Lipsky; Stefanie N Vogel; Eileen M Barry Journal: Infect Immun Date: 2012-04-16 Impact factor: 3.441
Authors: Zhaohua Lu; Guillermo Madico; Marly I Roche; Qi Wang; Julia H Hui; Hillary M Perkins; Joseph Zaia; Catherine E Costello; Jacqueline Sharon Journal: Immunology Date: 2012-07 Impact factor: 7.397
Authors: Roberto Biselli; Roberto Nisini; Florigio Lista; Alberto Autore; Marco Lastilla; Giuseppe De Lorenzo; Mario Stefano Peragallo; Tommaso Stroffolini; Raffaele D'Amelio Journal: Biomedicines Date: 2022-08-22
Authors: Aimee L Signarovitz; Heather J Ray; Jieh-Juen Yu; M N Guentzel; James P Chambers; Karl E Klose; Bernard P Arulanandam Journal: PLoS One Date: 2012-10-30 Impact factor: 3.240
Authors: Jon Cuccui; Rebecca M Thomas; Madeleine G Moule; Riccardo V D'Elia; Thomas R Laws; Dominic C Mills; Diane Williamson; Timothy P Atkins; Joann L Prior; Brendan W Wren Journal: Open Biol Date: 2013-05-22 Impact factor: 7.124